A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer
H Raza Ali, Sarah-Jane Dawson, Fiona M Blows, Elena Provenzano, Samuel Leung, Torsten Nielsen, Paul D Pharoah, Carlos Caldas
JOURNAL OF PATHOLOGY | WILEY-BLACKWELL | Published : 2012
There is an urgent need to improve prognostic classifiers in breast cancer. Ki67 and B-cell lymphoma 2 protein (BCL2) are established prognostic markers which have traditionally been assessed separately, in a dichotomous manner. This study was conducted to test the hypothesis that combinatorial assessment of these markers would provide superior prognostic information and improve their clinical utility. Tissue microarrays were used to assess the expression of Ki67 and BCL2 in 2749 cases of invasive breast cancer. We devised a Ki67/BCL2 index representing the relative expression of each protein and assessed its association with breast cancer-specific survival (BCSS) using a Cox proportional-ha..View full abstract
Awarded by National Institute for Health Research
Awarded by The Francis Crick Institute
We thank the participants of the contributing studies. HRA is supported by a fellowship funded by the NIHR Cambridge Biomedical Research Centre. SJD is supported by a fellowship funded by the Commonwealth Scholarship and Fellowship programme and Cancer Research UK. SEARCH is funded by a programme grant from Cancer Research UK. We acknowledge the contribution of the Histopathology Core Facility at the CRUK Cambridge Research Institute for immunohistochemical staining of the SEARCH series. The Genetic Pathology Evaluation Centre is supported in part by an unrestricted educational grant from Sanofi-aventis.